title: Is it time for HDL to change its tune?
authors.affiliation: South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia (S.J.N.); and Department of Cardiovascular Medicine and C5Research, Cleveland Clinic, Cleveland, OH (R.P.).
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Nicholls
authors.forename: Rishi
authors.initials: R
authors.lastname: Puri
mesh_terms: D008076:Cholesterol, HDL / Q000097:blood*; D005260:Female; D005464:Fluorobenzenes / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D011743:Pyrimidines / Q000627:therapeutic use*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D008076:Cholesterol, HDL; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium
keywords: Editorials; lipoproteins, HDL; statins, HMG-CoA